<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02839161</url>
  </required_header>
  <id_info>
    <org_study_id>HV-002</org_study_id>
    <nct_id>NCT02839161</nct_id>
  </id_info>
  <brief_title>Study of Co-administered Na-APR-1 (M74) and Na-GST-1 in Gabonese Children</brief_title>
  <official_title>Randomized, Controlled, Phase 1 Study to Assess Safety and Immunogenicity of Co-administered Hookworm Vaccine Candidates Na-APR-1 (M74)/Alhydrogel® and Na-GST-1/ Alhydrogel® in Gabonese Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double blind, randomized, controlled, dose-escalation Phase 1 clinical trial in&#xD;
      hookworm-exposed children aged 6 to 10 years living in the area of Lambaréné, Gabon. Children&#xD;
      will receive three doses of the Na-GST-1/Alhydrogel hookworm vaccine co-administered with the&#xD;
      Na-APR-1 (M74)/Alhydrogel hookworm vaccine or the hepatitis B vaccine co-administered with&#xD;
      sterile saline. All injections will be delivered intramuscularly (deltoid) on approximately&#xD;
      Days 0, 56, and 112 or 180.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Double blind, randomized, controlled, dose-escalation Phase 1 clinical trial in&#xD;
      hookworm-exposed children aged 6 to 10 years living in the area of Lambaréné, Gabon. Children&#xD;
      will receive three doses of the assigned vaccine(s) delivered intramuscularly (deltoid) on&#xD;
      approximately Days 0, 56, and 112 or 180.&#xD;
&#xD;
      Safety will be measured from the time of each study vaccination (Day 0) through 14 days after&#xD;
      each study vaccination by the occurrence of solicited injection site and systemic&#xD;
      reactogenicity events.&#xD;
&#xD;
      Unsolicited non-serious adverse events (AEs) will be collected from the time of the first&#xD;
      study vaccination through approximately 1 month after each study vaccination. New-onset&#xD;
      chronic medical conditions and Serious Adverse Events (SAEs) will be collected from the time&#xD;
      of the first study vaccination through approximately 9 months after the third study&#xD;
      vaccination (final visit). Clinical laboratory evaluations for safety will be performed on&#xD;
      venous blood collected approximately 14 days after each vaccination.&#xD;
&#xD;
      Immunogenicity testing will include IgG antibody responses to each vaccine antigen, by a&#xD;
      qualified indirect enzyme-linked immunosorbent assay (ELISA), on serum or plasma obtained&#xD;
      prior to each study vaccination and at time points after each vaccination (see Appendix A);&#xD;
      the functional activity of vaccine-induced antibodies will be assessed by in vitro enzyme&#xD;
      neutralization assays; the induction of B cell memory will be measured by antigen-specific&#xD;
      memory B cell responses.&#xD;
&#xD;
      Recruitment and enrollment into the study will occur on an ongoing basis, with each group&#xD;
      being recruited and vaccinated in sequence.&#xD;
&#xD;
      60 subjects will be enrolled into 3 groups of 20. The first 20 subjects will be assembled and&#xD;
      enrolled into Group 1:&#xD;
&#xD;
        1. Group 1 double-blind IP allocation (n=20):&#xD;
&#xD;
             -  16 subjects will receive 10 µg Na-APR-1 (M74) plus 5 µg GLA-AF delivered by IM&#xD;
                injection in the deltoid muscle, with 10 µg Na-GST-1 administered IM in the&#xD;
                alternate arm.&#xD;
&#xD;
                  -  8 will be vaccinated according to a 0,2,4-month schedule&#xD;
&#xD;
                  -  8 will be vaccinated according to a 0,2,6-month schedule&#xD;
&#xD;
             -  4 subjects will receive hepatitis B vaccine comparator:&#xD;
&#xD;
                  -  2 will be vaccinated according to a 0,2,4-month schedule&#xD;
&#xD;
                  -  2 will be vaccinated according to a 0,2,6-month schedule&#xD;
&#xD;
        2. Group 2 double-blind IP allocation (n=20):&#xD;
&#xD;
             -  16 subjects will receive 30 µg Na-APR-1 (M74) plus 5 µg GLA-AF delivered by IM&#xD;
                injection in the deltoid muscle, with 30µg Na-GST-1 administered IM in the&#xD;
                alternate arm.&#xD;
&#xD;
                  -  8 will be vaccinated according to a 0,2,4-month schedule&#xD;
&#xD;
                  -  8 will be vaccinated according to a 0,2,6-month schedule&#xD;
&#xD;
             -  4 subjects will receive hepatitis B vaccine comparator:&#xD;
&#xD;
                  -  2 will be vaccinated according to a 0,2,4-month schedule&#xD;
&#xD;
                  -  2 will be vaccinated according to a 0,2,6-month schedule&#xD;
&#xD;
        3. Group 3 double-blind IP allocation (n=20):&#xD;
&#xD;
             -  16 subjects will receive 100 µg Na-APR-1 (M74) plus 5 µg GLA-AF delivered by IM&#xD;
                injection in the deltoid muscle, with 100 µg Na-GST-1 administered IM in the&#xD;
                alternate arm.&#xD;
&#xD;
                  -  8 will be vaccinated according to a 0,2,4-month schedule&#xD;
&#xD;
                  -  8 will be vaccinated according to a 0,2,6-month schedule&#xD;
&#xD;
             -  4 subjects will receive hepatitis B vaccine comparator:&#xD;
&#xD;
                  -  2 will be vaccinated according to a 0,2,4-month schedule&#xD;
&#xD;
                  -  2 will be vaccinated according to a 0,2,6-month schedule&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Actual">March 28, 2019</completion_date>
  <primary_completion_date type="Actual">December 13, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vaccine-related Adverse Events</measure>
    <time_frame>Day 380</time_frame>
    <description>To evaluate the safety and reactogenicity of three different dose concentrations of Na-APR-1 (M74)/Alhydrogel® co-administered with Na-GST-1/Alhydrogel® in healthy Gabonese children.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IgG response to Na-GST-1 and Na-APR-1 (M74)</measure>
    <time_frame>14 days after the third vaccination</time_frame>
    <description>To determine the doses of co-administered Na-APR-1 (M74) and Na-GST-1 that result in the highest levels of IgG antibody approximately 14 days after the third vaccination.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Duration of antibody response to Na-GST-1 and Na-APR-1 (M74)</measure>
    <time_frame>Day 380</time_frame>
    <description>To assess and compare the duration of the antibody responses of Na-GST-1 and Na-APR-1 (M74).</description>
  </other_outcome>
  <other_outcome>
    <measure>IgG subclass response to Na-GST-1 and Na-APR-1 (M74)</measure>
    <time_frame>Day 380</time_frame>
    <description>To assess the distribution of IgG subclass responses to Na-GST-1 and Na-APR-1 (M74).</description>
  </other_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Hookworm Disease</condition>
  <condition>Hookworm Infection</condition>
  <arm_group>
    <arm_group_label>Low-dose (0,2,4 months)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 µg Na-APR-1 (M74) plus 5 µg GLA-AF delivered by IM injection in the deltoid muscle, with 10 µg Na-GST-1 administered IM in the alternate arm. Injections at 0, 2, and 4 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-dose (0,2,6 months)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 µg Na-APR-1 (M74) plus 5 µg GLA-AF delivered by IM injection in the deltoid muscle, with 10 µg Na-GST-1 administered IM in the alternate arm. Injections at 0, 2, and 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium-dose (0,2,4 months)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 µg Na-APR-1 (M74) plus 5 µg GLA-AF delivered by IM injection in the deltoid muscle, with 30 µg Na-GST-1 administered IM in the alternate arm. Injections at 0, 2, and 4 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium-dose (0,2,6 months)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 µg Na-APR-1 (M74) plus 5 µg GLA-AF delivered by IM injection in the deltoid muscle, with 30 µg Na-GST-1 administered IM in the alternate arm. Injections at 0, 2, and 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dose (0,2,4 months)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 µg Na-APR-1 (M74) plus 5 µg GLA-AF delivered by IM injection in the deltoid muscle, with 100 µg Na-GST-1 administered IM in the alternate arm. Injections at 0, 2, and 4 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dose (0,2,6 months)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 µg Na-APR-1 (M74) plus 5 µg GLA-AF delivered by IM injection in the deltoid muscle, with 100 µg Na-GST-1 administered IM in the alternate arm. Injections at 0, 2, and 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator (0,2,4 months)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hepatitis B vaccine delivered by IM injection in the deltoid muscle, with sterile saline solution administered IM in the alternate arm. Injections at 0, 2, and 4 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator (0,2,6 months)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hepatitis B vaccine delivered by IM injection in the deltoid muscle, with sterile saline solution administered IM in the alternate arm. Injections at 0, 2, and 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Na-GST-1/Alhydrogel</intervention_name>
    <arm_group_label>High-dose (0,2,4 months)</arm_group_label>
    <arm_group_label>High-dose (0,2,6 months)</arm_group_label>
    <arm_group_label>Low-dose (0,2,4 months)</arm_group_label>
    <arm_group_label>Low-dose (0,2,6 months)</arm_group_label>
    <arm_group_label>Medium-dose (0,2,4 months)</arm_group_label>
    <arm_group_label>Medium-dose (0,2,6 months)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Na-APR-1 (M74)/Alhydrogel</intervention_name>
    <arm_group_label>High-dose (0,2,4 months)</arm_group_label>
    <arm_group_label>High-dose (0,2,6 months)</arm_group_label>
    <arm_group_label>Low-dose (0,2,4 months)</arm_group_label>
    <arm_group_label>Low-dose (0,2,6 months)</arm_group_label>
    <arm_group_label>Medium-dose (0,2,4 months)</arm_group_label>
    <arm_group_label>Medium-dose (0,2,6 months)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hepatitis B Vaccine</intervention_name>
    <arm_group_label>Comparator (0,2,4 months)</arm_group_label>
    <arm_group_label>Comparator (0,2,6 months)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males or females between 6 and 10 years, inclusive, who are long-term residents of the&#xD;
             study area.&#xD;
&#xD;
          2. Good general health as determined by means of the screening procedure.&#xD;
&#xD;
          3. Assumed availability for the duration of the trial (up to 15 months).&#xD;
&#xD;
          4. Willingness of parent or legal guardian for child to participate in the study as&#xD;
             evidenced by signing the informed consent document in combination with the child&#xD;
             assent form.&#xD;
&#xD;
          5. Negative for hookworm during screening, or if found to be infected with hookworm, has&#xD;
             completed a course of three doses of albendazole.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Inability of parent/legal guardian to correctly answer all questions on the informed&#xD;
             consent comprehension questionnaire.&#xD;
&#xD;
          2. Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic,&#xD;
             rheumatologic, autoimmune, diabetes, or renal disease by history, physical&#xD;
             examination, and/or laboratory studies.&#xD;
&#xD;
          3. Known or suspected immunodeficiency.&#xD;
&#xD;
          4. Laboratory evidence of liver disease (alanine aminotransferase [ALT] greater than&#xD;
             1.25-times the upper reference limit).&#xD;
&#xD;
          5. Laboratory evidence of renal disease (serum creatinine greater than 1.25-times the&#xD;
             upper reference limit, or more than 1+ protein, or more than trace blood on urine&#xD;
             dipstick testing with the exception of greater than trace blood detected in females&#xD;
             during menses).&#xD;
&#xD;
          6. Laboratory evidence of hematologic disease (absolute leukocyte count &lt;4500/mm3;&#xD;
             absolute leukocyte count &gt;13.0 x 103/mm3; hemoglobin &lt;9.5 g/dl; or, platelet count&#xD;
             &lt;140,000/mm3).&#xD;
&#xD;
          7. Other condition that in the opinion of the investigator could jeopardize the safety or&#xD;
             rights of a child participating in the trial or would render the child unable to&#xD;
             comply with the protocol.&#xD;
&#xD;
          8. Participation in another investigational vaccine or drug trial within 30 days of&#xD;
             starting this study or for the duration of the study.&#xD;
&#xD;
          9. History of a severe allergic reaction or anaphylaxis.&#xD;
&#xD;
         10. Severe asthma as defined by the need for daily use of inhalers or emergency&#xD;
             room/clinic visit or hospitalization within 6 months of the child's planned first&#xD;
             vaccination in the study.&#xD;
&#xD;
         11. Positive for HCV.&#xD;
&#xD;
         12. Positive for HBsAg.&#xD;
&#xD;
         13. Positive for HIV infection.&#xD;
&#xD;
         14. Use of corticosteroids (excluding topical or nasal) or immunosuppressive drugs within&#xD;
             30 days of starting this study or expect to use for the duration of the study.&#xD;
&#xD;
         15. Receipt of a live vaccine within past 4 weeks or a killed vaccine within past 2 weeks&#xD;
             prior to entry into the study.&#xD;
&#xD;
         16. History of a surgical splenectomy.&#xD;
&#xD;
         17. Receipt of blood products within the 6 months prior to entry into the study.&#xD;
&#xD;
         18. Previous receipt of a primary series (three doses according to a 0, 1, and 6 -12 month&#xD;
             schedule) of the hepatitis B vaccine.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ayola Adegnika, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de Recherches Medicales de Lambaréné</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre de Recherches Médicales de Lambaréné</name>
      <address>
        <city>Lambaréné</city>
        <country>Gabon</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Gabon</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>July 18, 2016</study_first_submitted>
  <study_first_submitted_qc>July 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2016</study_first_posted>
  <last_update_submitted>April 2, 2019</last_update_submitted>
  <last_update_submitted_qc>April 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Maria Elena Bottazzi PhD</investigator_full_name>
    <investigator_title>Sponsor</investigator_title>
  </responsible_party>
  <keyword>Hookworm</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Na-GST-1</keyword>
  <keyword>Na-APR-1</keyword>
  <keyword>Necator americanus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hookworm Infections</mesh_term>
    <mesh_term>Ancylostomiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aluminum Hydroxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

